Company Overview and News

 
Lucapa Diamond Company recovers Lulo’s largest coloured diamond

2018-01-17 proactiveinvestors.com.au
Lucapa Diamond Co Ltd (ASX:LOM) has recovered the largest coloured gem-quality diamond to date from the Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa surges on Western Australian diamond results

2018-01-11 proactiveinvestors.com.au
Lucapa Diamond Co Ltd (ASX:LOM) surged after revealing the discovery of diamond-bearing material at the Brooking project in Western Australia.
Upvote Downvote

 
Lucapa Diamond Company granted trading halt to reveal results

2018-01-08 proactiveinvestors.com.au
Lucapa Diamond Company Ltd (ASX:LOM) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.
Upvote Downvote

 
Lucapa Diamond Company recovers more large diamonds in Angola

2018-01-08 proactiveinvestors.com.au
Lucapa Diamond Co Ltd (ASX:LOM) has recovered more large diamonds from the Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa Diamond Company schedules next sale of Lulo diamonds for early 2018

2017-12-19 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) and partners have scheduled the next sale of alluvial diamonds from the Lulo Diamond Project in Angola for early 2018.
Upvote Downvote

 
Lucapa Diamond Company drills multiple kimberlites at Lulo Diamond Project

2017-12-18 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has intersected a total of seven kimberlites near alluvial mining blocks 8, 6 and 28 as drilling continues on this cluster of targets at the Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa Diamond Company issues shares in lieu of fees

2017-11-20 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has issued 2.42 million shares in lieu of fees to Equigold Pte Ltd, the issuer of its recent US$15 million financing facility.
Upvote Downvote

 
Lucapa Diamond Company continues to sell Lulo diamonds for high prices

2017-11-20 proactiveinvestors.com.au
Lucapa Diamond Company Ltd (ASX:LOM) has completed another sale of 4,126 carats of Lulo diamonds, achieving gross proceeds of US$7.3 million.
Upvote Downvote

 
Lucapa Diamond Company has record October for mining

2017-11-15 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has achieved a record monthly treatment rate of 29,657 cubic metres for October 2017 at its 40% owned and operated Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa Diamond Company recovers high-value large diamond

2017-11-13 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has recovered a very large, high-value 129.58-carat diamond from the Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa Diamond Company finalises Mothae financing facility

2017-11-07 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has finalised all terms for the US$15 million financing facility with Equigold Pte Ltd and executed the legal agreements.
Upvote Downvote

 
Lucapa Diamond Company drills out kimberlite at multiple targets

2017-10-31 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) continues its drill program focused on kimberlite targets near and around Mining Block 8 located within the Lulo Diamond Project in Angola.
Upvote Downvote

 
Lucapa Diamond Company increases Mothae economics

2017-10-23 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has increased the value by 31% of its 70% owned Mothae kimberlite diamond project in Lesotho, southern Africa.
Upvote Downvote

 
Lucapa Diamond Company secures debt financing to develop Mothae

2017-10-09 proactiveinvestors.com.au
Lucapa Diamond Company (ASX:LOM) has secured a US$15 million (A$19 million) financing facility to develop Phase 1 of the Mothae kimberlite diamond project in Lesotho.
Upvote Downvote

 
Lucapa to outline financing development for Mothae diamond project

2017-10-05 proactiveinvestors.com.au
Lucapa Diamond Company Ltd (ASX:LOM) has been granted a trading halt by the ASX this morning, pending details on financing for the development of the high-value Mothae kimberlite diamond project in Lesotho, in Southern Africa.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...